These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 23750862)

  • 1. Prognostic factors affecting disease-specific survival in patients with recurrent and/or metastatic differentiated thyroid carcinoma detected by positron emission tomography/computed tomography.
    Akkas BE; Demirel BB; Vural GU
    Thyroid; 2014 Feb; 24(2):287-95. PubMed ID: 23750862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management and outcome of recurrent well-differentiated thyroid carcinoma.
    Palme CE; Waseem Z; Raza SN; Eski S; Walfish P; Freeman JL
    Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):819-24. PubMed ID: 15262757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data.
    Vural GU; Akkas BE; Ercakmak N; Basu S; Alavi A
    Clin Nucl Med; 2012 Oct; 37(10):953-9. PubMed ID: 22899202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
    Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
    Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of 18F-FDG PET/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients.
    Lee JW; Lee SM; Lee DH; Kim YJ
    J Nucl Med; 2013 Aug; 54(8):1230-6. PubMed ID: 23813775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent disease in juvenile differentiated thyroid carcinoma: prognostic factors, treatments, and outcomes.
    Mihailovic J; Nikoletic K; Srbovan D
    J Nucl Med; 2014 May; 55(5):710-7. PubMed ID: 24722527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
    Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preablative Stimulated Thyroglobulin Levels Can Predict Malignant Potential and Therapeutic Responsiveness of Subcentimeter-Sized, 18F-fluorodeoxyglucose-Avid Cervical Lymph Nodes in Patients With Papillary Thyroid Cancer.
    Kwon SY; Kim J; Jung SH; Chong A; Song HC; Bom HS; Min JJ
    Clin Nucl Med; 2016 Jan; 41(1):e32-8. PubMed ID: 26164179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PROGNOSTIC VALUE OF LYMPH NODE UPTAKE ON PRETREATMENT F-18 FDG PET/CT IN PATIENTS WITH N1B PAPILLARY THYROID CARCINOMA.
    Lee CH; Lee SW; Son SH; Hong CM; Jeong JH; Jeong SY; Ahn BC; Lee J
    Endocr Pract; 2019 Aug; 25(8):787-793. PubMed ID: 31013158
    [No Abstract]   [Full Text] [Related]  

  • 10. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine.
    Wang W; Larson SM; Tuttle RM; Kalaigian H; Kolbert K; Sonenberg M; Robbins RJ
    Thyroid; 2001 Dec; 11(12):1169-75. PubMed ID: 12186505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy.
    Vassilopoulou-Sellin R; Schultz PN; Haynie TP
    Cancer; 1996 Aug; 78(3):493-501. PubMed ID: 8697396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors of follicular thyroid carcinoma.
    Ríos A; Rodríguez JM; Ferri B; Martínez-Barba E; Torregrosa NM; Parrilla P
    Endocrinol Nutr; 2015 Jan; 62(1):11-8. PubMed ID: 25156926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning.
    Robbins RJ; Wan Q; Grewal RK; Reibke R; Gonen M; Strauss HW; Tuttle RM; Drucker W; Larson SM
    J Clin Endocrinol Metab; 2006 Feb; 91(2):498-505. PubMed ID: 16303836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma.
    Rivera M; Ghossein RA; Schoder H; Gomez D; Larson SM; Tuttle RM
    Cancer; 2008 Jul; 113(1):48-56. PubMed ID: 18484584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Positron emission tomography-computed tomography with (18)F-fluorodeoxyglucose in patients with recurrent differentiated thyroid carcinoma and negative radioiodine scan. Diagnostic performance and relation with tyroglobulin levels].
    Mariscal Labrador E; García Burillo A; Castell-Conesa J; Obiols Alfonso G; Kisiel González N; Barios Profitós M; Aguadé-Bruix S; Mesa Manteca J
    Rev Esp Med Nucl Imagen Mol; 2013; 32(3):146-51. PubMed ID: 22726673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes of distant metastasis from differentiated thyroid carcinoma.
    Huang IC; Chou FF; Liu RT; Tung SC; Chen JF; Kuo MC; Hsieh CJ; Wang PW
    Clin Endocrinol (Oxf); 2012 Mar; 76(3):439-47. PubMed ID: 21950769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorodeoxyglucose-positron emission tomography scan-positive recurrent papillary thyroid cancer and the prognosis and implications for surgical management.
    Schreinemakers JM; Vriens MR; Munoz-Perez N; Guerrero MA; Suh I; Rinkes IH; Gosnell J; Shen WT; Clark OH; Duh QY
    World J Surg Oncol; 2012 Sep; 10():192. PubMed ID: 22985118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis.
    Sampson E; Brierley JD; Le LW; Rotstein L; Tsang RW
    Cancer; 2007 Oct; 110(7):1451-6. PubMed ID: 17705176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?
    Deandreis D; Al Ghuzlan A; Leboulleux S; Lacroix L; Garsi JP; Talbot M; Lumbroso J; Baudin E; Caillou B; Bidart JM; Schlumberger M
    Endocr Relat Cancer; 2011 Feb; 18(1):159-69. PubMed ID: 21118976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of total thyroidectomy with therapeutic central and lateral neck dissection with a single dose of radioiodine in the treatment of regionally advanced papillary thyroid cancer and effects on serum thyroglobulin.
    Hughes DT; Miller BS; Cohen MS; Doherty GM; Gauger PG
    Ann Surg Oncol; 2014 May; 21(5):1647-52. PubMed ID: 24385210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.